Drug Delivery

THERAPEUTIC FOCUS: Sufentanil NanoTab Technology: Revolutionizing Patient-Controlled Analgesia

Pamela P. Palmer, MD, PhD; examines how AcelRx’s system can deliver the benefits of PCA in terms of patient pain relief and satisfaction while reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing the cost burden on the healthcare system.

EXECUTIVE INTERVIEW – Agere: Solubilization: Accessing Broader Chemistries by Integrating Fundamental Science With Automation for Greater Predictability

Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.

PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs

Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.

DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery

Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.

EXCLUSIVE ONLINE CONTENT